

**Testimony Submitted by
Angela Donley, State Policy Director
Oregon Consumer Justice
To the House Committee on Rules**

March 2, 2026

Regarding: Support for SB 1528 A

Chair Bowman, Vice-Chair Elmer, Vice-Chair Pham, and Members of the Committee,

For the record, my name is Angela Donley. I appreciate the opportunity to provide testimony on behalf of Oregon Consumer Justice in support of SB 1528 A.

Oregon Consumer Justice (OCJ) envisions a vibrant future where all Oregonians live with dignity and abundance and experience health, joy, and economic opportunity. We work collaboratively across policy and advocacy, community engagement, and the law, to realize a more just and equitable Oregon where people come first. For too long, flawed systems and policies have stood in the way of this reality, with communities of color most often experiencing significant harm. Informed by consumer insights, OCJ works to make financial and business transactions reliably safe and supports Oregonians in knowing and exercising their consumer rights.

At OCJ, we believe consumers deserve transparency in the markets that shape their financial and physical well-being. When Oregonians fill a prescription, they should have confidence that the system delivers effective treatment at a fair and sustainable cost, not one that quietly drives prices higher elsewhere.

As healthcare costs continue to rise, affordability remains a top concern for Oregon families. Drug manufacturers often point to patient assistance programs as proof that they are helping consumers afford their medications. On the surface, these programs can provide short-term relief by lowering a patient's copay. But behind the scenes, these programs can obscure the actual cost of medications and shift expenses across the healthcare system, ultimately driving up premiums and out-of-pocket costs for Oregon families. Current law requires reporting on some patient assistance programs, but a loophole allows many manufacturer-sponsored programs to go unreported. This gap prevents the state from understanding how widespread these practices are and how

significantly they may be contributing to rising healthcare costs. Without comprehensive reporting, policymakers, the healthcare system, and the public lack a clear picture of how these programs influence pricing decisions, prescribing patterns, and overall healthcare costs.

SB 1528 A requires drug companies to report on information they already gather and be transparent about the impact of all of Oregon's patient assistance programs. This will not eliminate patient assistance programs. Instead, it will ensure Oregon has better visibility into hidden healthcare cost pressures and the tools to promote a system where opaque pricing strategies do not undermine effective, lower-cost treatments.

We urge you to support SB 1528 A and take an essential step toward a healthcare system that is transparent, sustainable, and centered on the needs of Oregon consumers.

Thank you for your consideration and your service in building the future that Oregonians deserve.

